PureTech Spins Out Celea Therapeutics to Advance IPF Drug Candidate

PureTech has launched a new subsidiary, Celea Therapeutics, dedicated to developing therapies for respiratory diseases, notably idiopathic pulmonary fibrosis (IPF)1 2 3 5.

Celea’s lead candidate is deupirfenidone (LYT-100), a deuterated analogue of pirfenidone, designed to improve efficacy and safety for fibrotic and inflammatory lung diseases1 2 3 5.

The unit is led by Dr. Sven Dethlefs, former CEO of Teva North America, credited for his prior success with deuterated drugs1 2 5.

Phase 2b data for deupirfenidone showed best-in-class potential with a favorable safety profile; Celea plans to initiate phase 3 trials by the end of Q3 20251 2.

PureTech aims to seek external funding to support Celea through the phase 3 program and potential commercialization2.

Sources:

1. https://www.fiercebiotech.com/biotech/puretech-launches-celea-therapeutics-develop-highly-touted-lung-disease-candidate

2. https://www.ajbell.co.uk/news/articles/puretech-health-launches-new-vehicle-lung-disease-drug-candidate

3. https://firstwordpharma.com/story/5988322

5. https://www.europeanpharmaceuticalreview.com/news/264646/puretech-teva-respiratory-deupirfenidone-celea-sven-dethlefs/

Sources:

Leave a Reply Cancel reply